Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 192

1.

American Thyroid Association Scientific Statement on the Use of Potassium Iodide Ingestion in a Nuclear Emergency.

Leung AM, Bauer AJ, Benvenga S, Brenner AV, Hennessey JV, Hurley JR, Milan SA, Schneider AB, Sundaram K, Toft DJ.

Thyroid. 2017 Jul;27(7):865-877. doi: 10.1089/thy.2017.0054. Epub 2017 Jun 21.

2.

αB-crystallin and HspB2 deficiency is protective from diet-induced glucose intolerance.

Toft DJ, Fuller M, Schipma M, Chen F, Cryns VL, Layden BT.

Genom Data. 2016 May 13;9:10-7. doi: 10.1016/j.gdata.2016.03.010. eCollection 2016 Sep.

3.

pH and amphiphilic structure direct supramolecular behavior in biofunctional assemblies.

Moyer TJ, Finbloom JA, Chen F, Toft DJ, Cryns VL, Stupp SI.

J Am Chem Soc. 2014 Oct 22;136(42):14746-52. doi: 10.1021/ja5042429. Epub 2014 Oct 13.

4.

Qualification of LSP1-2111 as a Brain Penetrant Group III Metabotropic Glutamate Receptor Orthosteric Agonist.

Cajina M, Nattini M, Song D, Smagin G, Jørgensen EB, Chandrasena G, Bundgaard C, Toft DB, Huang X, Acher F, Doller D.

ACS Med Chem Lett. 2013 Dec 12;5(2):119-23. doi: 10.1021/ml400338f. eCollection 2014 Feb 13.

5.

Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies.

Hornberg JJ, Laursen M, Brenden N, Persson M, Thougaard AV, Toft DB, Mow T.

Drug Discov Today. 2014 Aug;19(8):1137-44. doi: 10.1016/j.drudis.2013.12.009. Epub 2013 Dec 25. Review.

PMID:
24374152
6.

Exploratory toxicology as an integrated part of drug discovery. Part I: Why and how.

Hornberg JJ, Laursen M, Brenden N, Persson M, Thougaard AV, Toft DB, Mow T.

Drug Discov Today. 2014 Aug;19(8):1131-6. doi: 10.1016/j.drudis.2013.12.008. Epub 2013 Dec 22. Review.

PMID:
24368175
7.

Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.

Saif MW, Erlichman C, Dragovich T, Mendelson D, Toft D, Burrows F, Storgard C, Von Hoff D.

Cancer Chemother Pharmacol. 2013 May;71(5):1345-55. doi: 10.1007/s00280-013-2134-9. Epub 2013 Apr 6.

PMID:
23564374
8.

Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.

Schenk E, Hendrickson AE, Northfelt D, Toft DO, Ames MM, Menefee M, Satele D, Qin R, Erlichman C.

Invest New Drugs. 2013 Oct;31(5):1251-6. doi: 10.1007/s10637-013-9946-7. Epub 2013 Mar 31.

9.

Coassembled cytotoxic and pegylated peptide amphiphiles form filamentous nanostructures with potent antitumor activity in models of breast cancer.

Toft DJ, Moyer TJ, Standley SM, Ruff Y, Ugolkov A, Stupp SI, Cryns VL.

ACS Nano. 2012 Sep 25;6(9):7956-65. Epub 2012 Aug 28.

10.

Antitumor activity of peptide amphiphile nanofiber-encapsulated camptothecin.

Soukasene S, Toft DJ, Moyer TJ, Lu H, Lee HK, Standley SM, Cryns VL, Stupp SI.

ACS Nano. 2011 Nov 22;5(11):9113-21. doi: 10.1021/nn203343z. Epub 2011 Nov 1.

11.

Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies.

Toft DJ, Cryns VL.

Mol Endocrinol. 2011 Feb;25(2):199-211. doi: 10.1210/me.2010-0164. Epub 2010 Sep 22. Review.

12.

Induction of cancer cell death by self-assembling nanostructures incorporating a cytotoxic peptide.

Standley SM, Toft DJ, Cheng H, Soukasene S, Chen J, Raja SM, Band V, Band H, Cryns VL, Stupp SI.

Cancer Res. 2010 Apr 15;70(8):3020-6. doi: 10.1158/0008-5472.CAN-09-3267. Epub 2010 Mar 30.

13.

Characterization of plant p23-like proteins for their co-chaperone activities.

Zhang Z, Sullivan W, Felts SJ, Prasad BD, Toft DO, Krishna P.

Cell Stress Chaperones. 2010 Sep;15(5):703-15. doi: 10.1007/s12192-010-0182-1. Epub 2010 Mar 28.

14.

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.

Hubbard J, Erlichman C, Toft DO, Qin R, Stensgard BA, Felten S, Ten Eyck C, Batzel G, Ivy SP, Haluska P.

Invest New Drugs. 2011 Jun;29(3):473-80. doi: 10.1007/s10637-009-9381-y. Epub 2010 Jan 15.

15.

FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells.

Ni L, Yang CS, Gioeli D, Frierson H, Toft DO, Paschal BM.

Mol Cell Biol. 2010 Mar;30(5):1243-53. doi: 10.1128/MCB.01891-08. Epub 2010 Jan 4.

16.

Primary CNS lymphoma with bilateral symmetric hypothalamic lesions presenting with panhypopituitarism and diabetes insipidus.

Layden BT, Dubner S, Toft DJ, Kopp P, Grimm S, Molitch ME.

Pituitary. 2011 Jun;14(2):194-7. doi: 10.1007/s11102-008-0166-7.

17.

Cisplatin abrogates the geldanamycin-induced heat shock response.

McCollum AK, Lukasiewicz KB, Teneyck CJ, Lingle WL, Toft DO, Erlichman C.

Mol Cancer Ther. 2008 Oct;7(10):3256-64. doi: 10.1158/1535-7163.MCT-08-0157.

18.

P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response.

McCollum AK, TenEyck CJ, Stensgard B, Morlan BW, Ballman KV, Jenkins RB, Toft DO, Erlichman C.

Cancer Res. 2008 Sep 15;68(18):7419-27. doi: 10.1158/0008-5472.CAN-07-5175.

19.

Role of the cochaperone Tpr2 in Hsp90 chaperoning.

Moffatt NS, Bruinsma E, Uhl C, Obermann WM, Toft D.

Biochemistry. 2008 Aug 5;47(31):8203-13. doi: 10.1021/bi800770g. Epub 2008 Jul 12.

PMID:
18620420
20.

Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions.

Smith DF, Toft DO.

Mol Endocrinol. 2008 Oct;22(10):2229-40. doi: 10.1210/me.2008-0089. Epub 2008 May 1. Review.

21.

Recent Advances in the Study of hsp90 Structure and Mechanism of Action.

Toft DO.

Trends Endocrinol Metab. 1998 Aug;9(6):238-43.

PMID:
18406275
22.

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.

Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo MS, Toft D, Jiang SW, Slamon DJ, Podratz KC.

Br J Cancer. 2008 Mar 25;98(6):1076-84. doi: 10.1038/sj.bjc.6604278. Epub 2008 Mar 11.

23.

GCUNC45 is the first Hsp90 co-chaperone to show alpha/beta isoform specificity.

Chadli A, Felts SJ, Toft DO.

J Biol Chem. 2008 Apr 11;283(15):9509-12. doi: 10.1074/jbc.C800017200. Epub 2008 Feb 19.

24.

Functioning of the Hsp90 machine in chaperoning checkpoint kinase I (Chk1) and the progesterone receptor (PR).

Felts SJ, Karnitz LM, Toft DO.

Cell Stress Chaperones. 2007 Winter;12(4):353-63.

25.

Analysis of Hsp90 cochaperone interactions reveals a novel mechanism for TPR protein recognition.

Chadli A, Bruinsma ES, Stensgard B, Toft D.

Biochemistry. 2008 Mar 4;47(9):2850-7. doi: 10.1021/bi7023332. Epub 2008 Jan 23.

PMID:
18211007
26.

An acetylation site in the middle domain of Hsp90 regulates chaperone function.

Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K, Cotter RJ, Felts S, Toft D, Karnitz L, Rosen N, Neckers L.

Mol Cell. 2007 Jan 12;25(1):151-9.

27.

Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism.

McCollum AK, Teneyck CJ, Sauer BM, Toft DO, Erlichman C.

Cancer Res. 2006 Nov 15;66(22):10967-75.

28.

A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer.

Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, Erlichman C.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6087-93.

29.

Defining the requirements for Hsp40 and Hsp70 in the Hsp90 chaperone pathway.

Cintron NS, Toft D.

J Biol Chem. 2006 Sep 8;281(36):26235-44. Epub 2006 Jul 19.

30.

GCUNC-45 is a novel regulator for the progesterone receptor/hsp90 chaperoning pathway.

Chadli A, Graham JD, Abel MG, Jackson TA, Gordon DF, Wood WM, Felts SJ, Horwitz KB, Toft D.

Mol Cell Biol. 2006 Mar;26(5):1722-30.

31.

Chaperoning checkpoint kinase 1 (Chk1), an Hsp90 client, with purified chaperones.

Arlander SJ, Felts SJ, Wagner JM, Stensgard B, Toft DO, Karnitz LM.

J Biol Chem. 2006 Feb 3;281(5):2989-98. Epub 2005 Dec 5.

32.

HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.

Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP.

Mol Cell. 2005 May 27;18(5):601-7.

33.

Structures of the N-terminal and middle domains of E. coli Hsp90 and conformation changes upon ADP binding.

Huai Q, Wang H, Liu Y, Kim HY, Toft D, Ke H.

Structure. 2005 Apr;13(4):579-90.

34.

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.

Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, Adjei AA, Sloan J, Atherton P, Vasile V, Salazaar S, Adjei A, Croghan G, Erlichman C.

J Clin Oncol. 2005 Feb 20;23(6):1078-87.

PMID:
15718306
35.

Hsp90: from structure to phenotype.

Jackson SE, Queitsch C, Toft D.

Nat Struct Mol Biol. 2004 Dec;11(12):1152-5. No abstract available.

PMID:
15578051
36.

Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function.

Hu J, Flores D, Toft D, Wang X, Nguyen D.

J Virol. 2004 Dec;78(23):13122-31.

37.

Interaction of the Hsp90 cochaperone cyclophilin 40 with Hsc70.

Carrello A, Allan RK, Morgan SL, Owen BA, Mok D, Ward BK, Minchin RF, Toft DO, Ratajczak T.

Cell Stress Chaperones. 2004 Summer;9(2):167-81.

38.

A novel in situ assay for the identification and characterization of soluble nuclear mobility factors.

Elbi C, Walker DA, Lewis M, Romero G, Sullivan WP, Toft DO, Hager GL, DeFranco DB.

Sci STKE. 2004 Jun 22;2004(238):pl10.

PMID:
15213337
39.

Molecular chaperones function as steroid receptor nuclear mobility factors.

Elbi C, Walker DA, Romero G, Sullivan WP, Toft DO, Hager GL, DeFranco DB.

Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2876-81. Epub 2004 Feb 20.

40.

p23, a simple protein with complex activities.

Felts SJ, Toft DO.

Cell Stress Chaperones. 2003 Summer;8(2):108-13. Review.

41.

Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress.

Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO, Karnitz LM.

J Biol Chem. 2003 Dec 26;278(52):52572-7. Epub 2003 Oct 21.

42.

Novel activation step required for transcriptional competence of progesterone receptor on chromatin templates.

Thackray VG, Toft DO, Nordeen SK.

Mol Endocrinol. 2003 Dec;17(12):2543-53. Epub 2003 Oct 9.

PMID:
14551264
43.

Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation.

Wang L, Sullivan W, Toft D, Weinshilboum R.

Pharmacogenetics. 2003 Sep;13(9):555-64.

PMID:
12972954
44.

The Hsp90 chaperone complex as a novel target for cancer therapy.

Goetz MP, Toft DO, Ames MM, Erlichman C.

Ann Oncol. 2003 Aug;14(8):1169-76. Review.

PMID:
12881371
45.

Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery.

Pratt WB, Toft DO.

Exp Biol Med (Maywood). 2003 Feb;228(2):111-33. Review.

PMID:
12563018
46.

The influence of ATP and p23 on the conformation of hsp90.

Sullivan WP, Owen BA, Toft DO.

J Biol Chem. 2002 Nov 29;277(48):45942-8. Epub 2002 Sep 24.

47.

The assembly and intermolecular properties of the hsp70-Hop-hsp90 molecular chaperone complex.

Hernández MP, Sullivan WP, Toft DO.

J Biol Chem. 2002 Oct 11;277(41):38294-304. Epub 2002 Aug 2.

48.

HSP70 and HSP90 expression in leucocytes after exercise in moderately trained humans.

Shastry S, Toft DO, Joyner MJ.

Acta Physiol Scand. 2002 Jun;175(2):139-46.

PMID:
12028134
49.

Effect of geldanamycin on androgen receptor function and stability.

Vanaja DK, Mitchell SH, Toft DO, Young CY.

Cell Stress Chaperones. 2002 Jan;7(1):55-64.

50.

HSP40 binding is the first step in the HSP90 chaperoning pathway for the progesterone receptor.

Hernández MP, Chadli A, Toft DO.

J Biol Chem. 2002 Apr 5;277(14):11873-81. Epub 2002 Jan 23.

Supplemental Content

Support Center